ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2012

A Phase IIb, Randomized, Double-blind Study in Patients with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Patients with an Inadequate Response to Methotrexate

Charles Peterfy1, Maya Buch2, Ernest Choy3, Georg Schett4, Dana Parsons-Rich5, Anand Patel6, Yulia Zima5, Claire Le Bolay7 and Mark Genovese8, 1Spire Sciences, Inc., Boca Raton, FL, 2Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, 3CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, 4Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, 5EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 6EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, 7Merck KGaA, Darmstadt, Germany, 8Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA

Meeting: ACR Convergence 2020

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards), Magnetic resonance imaging (MRI), Randomized Trial, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 9, 2020

Session Title: RA – Treatments IV: New Therapies & Strategies (2008–2012)

Session Type: Abstract Session

Session Time: 5:00PM-5:50PM

Background/Purpose: Bruton’s tyrosine kinase (BTK) is involved in multiple signalling pathways potentially implicated in rheumatoid arthritis (RA). Evobrutinib is a highly selective, oral BTK inhibitor. This phase IIb, randomized, double-blind study evaluated efficacy, dose response, and safety to 12 weeks of treatment with evobrutinib versus placebo in RA patients with inadequate response to methotrexate (MTX).

Methods: Patients enrolled were 18–75 years of age, with confirmed diagnosis of RA ≥ 6 months duration (EULAR/American College of Rheumatology [ACR] criteria), with active disease at screening and randomization, defined by ≥ 6 swollen and ≥ 6 tender joints, and with high-sensitivity CRP (hsCRP) ≥ 5.0 mg/L. Participants had received MTX treatment 7.5–25 mg/week for ≥ 16 weeks at stable dose for ≥ 8 weeks, and had not received prior treatment with a biologic DMARD. They were randomized 1:1:1:1 to oral evobrutinib 25 mg once-daily (QD), 75 mg QD, 50 mg twice-daily (BID), or placebo. Stable use of NSAIDs and/or glucocorticoids (≤10 mg daily) was allowed. The primary endpoint was ACR 20% response (ACR20), assessed at Week 12, using hsCRP. Key secondary endpoints were ACR50 and ACR70 and disease activity scores (DAS28)CRP, DAS28CRP < 3.2 and DAS28CRP < 2.6. Safety endpoints included adverse events (AEs), serious AEs (SAEs), and laboratory studies. Other secondary endpoints included change from baseline in OMERACT RAMRIS scores and RAMRIQ scores for synovitis, osteitis and erosion for patients in an MRI substudy.

Results: 390 patients were randomized. Baseline age was 52.7±12.2 years (mean±SD), 80.0% were female, hsCRP 21.77mg/L ±24.1 (mean±SD), and time since diagnosis 6.9±6.7 years (mean±SD). The treatment groups were balanced for sex, race, age, time since diagnosis, joint counts, and other baseline disease characteristics. The primary endpoint of ACR20 response was not met (Figure 1). ACR20 response in the placebo group (49.5%) was higher than other trials in RA. Evobrutinib at all doses was nominally significant versus placebo on DAS28CRP < 3.2, and DAS28CRP < 2.6. HsCRP decreased in all evobrutinib arms (Table 1). No dose response was observed. There were no significant differences in MRI scores between placebo and evobrutinib by either RAMRIS (Table 1) or RAMRIQ (data not shown). Evobrutinib was well tolerated at all doses (Table 2). Three patients showed Grade 3 elevations in ALT, all in the 75 mg QD arm. LFT elevations were reported across all groups. Very few patients experienced Grade 3 events, and only one patient experienced a Grade 4 event (unrelated to treatment).

Conclusion: This phase IIb study of evobrutinib in patients with RA with inadequate response to MTX did not meet its primary efficacy endpoint of ACR20 response. MRI endpoints did not show differences between evobrutinib and placebo. However, MRI placebo scores were not consistent with other studies, showing greater improvements in synovitis and osteitis, and less progression of erosions than typically reported.  Evobrutinib was well tolerated at all doses. No dose effect was identified.


Disclosure: C. Peterfy, AbbVie, 1, Acerta, 1, Amgen, 1, 2, Astra Zeneca, 1, Bristol-Myers Squibb, 1, Centrexion, 1, Daiichi Sankyo, 1, Five Prime Therapeutics, 1, Genentech, 1, Gilead, 1, Hoffman-La Roche, 1, Janssen, 1, Lilly, 1, Medimmune, 1, Merck & Co, 1, Myriad, 1, Novartis, 1, Plexxikon, 1, Pfizer, 1, Sanofi, 1, Salix Santarus, 1, Samsung, 1, Samumed, 1, Setpoint, 1, Sorrento, 1, UCB, 1, Vorso, 1, Spire Sciences, 1, 2, 3; M. Buch, Pfizer, 2, Roche, 2, UCB, 2, AbbVie, 5, Eli Lilly and Company, 5, Gilead Sciences, Inc., 5, Merck-Serono, 5, Sandoz, 5, Sanofi, 5; E. Choy, Abbvie, 2, 8, Amgen, 2, 8, AstraZeneca, 2, 8, Biogen, 2, 8, Bio-Cancer, 2, 8, Boehringer Ingelheim, 2, 8, Bristol-Myers Squibb, 2, 8, Celgene, 2, 8, Chugai Pharma, 2, 8, Eli Lilly, 2, 8, Ferring Pharmaceuticals, 2, 8, GlaxoSmithKline, 2, 8, Janssen, 2, 8, Novartis, 2, 8, Novimmune, 2, 8, ObsEva, 2, 8, Pfizer, 2, 8, R-Pharm, 2, 8, Roche, 2, 8, SynAct Pharma, 2, 8, Tonix, 2, 8, UCB, 2, 8, Synovate, 2, 8, Sanofi, 2, 8, Regeneron, 2, 8, Napp, 2, 8, Hospira, 2, 8, Merck Sharp & Dohme, 2, 8; G. Schett, None; D. Parsons-Rich, EMD Serono, Inc. (a business of Merck KGaA, Darmstadt, Germany), 1, 3; A. Patel, EMD Serono, 3; Y. Zima, EMD Serono, Inc. (a business of Merck KGaA, Darmstadt, Germany), 3; C. Le Bolay, Merck Healthcare KGaA, 3; M. Genovese, Gilead, 2, 5, Galapagos, 2, 5, Lilly, 2, 5, AbbVie, 2, 5, Pfizer, 2, 5, Astellas, 2, 5, Vertex, 2, 5, Sanofi, 2, 5, EMD Serono, 2, 5, Genentech/Roche, 2, 5, Incyte, 2, 5.

To cite this abstract in AMA style:

Peterfy C, Buch M, Choy E, Schett G, Parsons-Rich D, Patel A, Zima Y, Le Bolay C, Genovese M. A Phase IIb, Randomized, Double-blind Study in Patients with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Patients with an Inadequate Response to Methotrexate [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/a-phase-iib-randomized-double-blind-study-in-patients-with-rheumatoid-arthritis-evaluating-the-safety-and-efficacy-of-evobrutinib-compared-with-placebo-in-patients-with-an-inadequate-response-to-met/. Accessed March 1, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-phase-iib-randomized-double-blind-study-in-patients-with-rheumatoid-arthritis-evaluating-the-safety-and-efficacy-of-evobrutinib-compared-with-placebo-in-patients-with-an-inadequate-response-to-met/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.